MAM
URGN icon

Meeder Asset Management’s UroGen Pharma URGN Stock Holding History

Meeder Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-304
Closed -$10K – 2541
2019
Q4 		$10K Buy
304
+206
+210% +$5.62K ﹤0.01% 1570
2019
Q3 		$2K Buy
+98
New +$3.2K ﹤0.01% 1991

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Asset Management's URGN Position: Q1 2020 in Review

Meeder Asset Management sold out of UroGen Pharma (URGN) in Q1 2020, closing a stake of 304 shares — an estimated $10K sold.

Meeder Asset Management first reported a position in URGN in Q3 2019 and held it in 2 quarters. The position peaked at $10K in Q4 2019. 79 funds tracked by Wall St. Rank hold URGN as of Q1 2020.

  • Meeder Asset Management reported no remaining UroGen Pharma position as of Q1 2020 after selling out during the quarter.
  • Meeder Asset Management sold 304 UroGen Pharma shares in Q1 2020, an estimated $10K.
  • Meeder Asset Management first reported a position in UroGen Pharma in Q3 2019 and held it in 2 quarters.
  • Meeder Asset Management's UroGen Pharma position peaked at $10K in Q4 2019.
  • 79 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2020.

Based on Meeder Asset Management's 13F filing for Q1 2020, filed 15 May 2020.